The Scottish Medicines Consortium (SMC) has accepted AbbVie’s Aquipta (atogepant) as an option for the acute treatment of migraine with or without aura in adults meeting specified criteria. The recommendation applies where at least two triptans – medicines prescribed for migraine symptoms – have failed to provide adequate relief, are contraindicated or have not been […]
The post SMC accepts atogepant for acute migraine treatment in Scotland appeared first on Pharmafile.